Curis Inc
NASDAQ:CRIS
Curis Inc
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.
Clinical Progress: Curis made steady progress in its TakeAim Lymphoma study evaluating emavusertib with ibrutinib in primary CNS lymphoma, and is preparing for accelerated submissions in the U.S. and Europe.
CLL Program Advancement: The company is moving forward with a proof-of-concept study of emavusertib added to BTKi in CLL patients, with site activation underway and first enrollment expected late Q4 or early Q1.
AML Triplet Data: Initial results from the AML triplet study showed MRD conversion to undetectable levels in 4 of 8 evaluable patients, with manageable safety signals.
Financials: Net loss narrowed to $7.7 million for Q3 2025, down from $10.1 million a year ago, with reduced R&D and G&A expenses.
Cash Runway: Cash and cash equivalents of $9.1 million are expected to fund operations into 2026, but management signaled a need to raise additional capital by year-end.
Upcoming Milestones: Multiple data updates are expected at SNO and ASH conferences in the coming weeks.
